Bide Pharmatech Co., Ltd. (SHA:688073)
China · Delayed Price · Currency is CNY 74.91
+4.43 (6.29%)
At close: Aug 20, 2026
Bide Pharmatech Revenue
Bide Pharmatech had revenue of 323.28M CNY in the quarter ending March 31, 2026, with 9.08% growth. This brings the company's revenue in the last twelve months to 1.35B, up 18.93% year-over-year. In the year 2025, Bide Pharmatech had annual revenue of 1.32B with 20.13% growth.
Revenue (ttm)
1.35B
Revenue Growth
+18.93%
P/S Ratio
4.78
Revenue / Employee
1.84M
Employees
734
Market Cap
6.45B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.32B | 221.80M | 20.13% |
| Dec 31, 2024 | 1.10B | 10.15M | 0.93% |
| Dec 31, 2023 | 1.09B | 258.03M | 30.94% |
| Dec 31, 2022 | 833.83M | 227.61M | 37.55% |
| Dec 31, 2021 | 606.22M | 214.75M | 54.86% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| HPGC Renmintongtai Pharmaceutical | 10.64B |
| China Animal Husbandry Industry | 6.45B |
| KPC Pharmaceuticals,Inc. | 5.80B |
| Cisen Pharmaceutical | 3.37B |
| Jiangsu Kanion Pharmaceutical | 3.25B |
| Tianjin Tianyao Pharmaceuticals | 2.73B |
| Guangxi Wuzhou Zhongheng Group | 1.58B |
| Hunan Er-Kang Pharmaceutical | 1.06B |